Multiple TRODELVYᵀᴹ molecules housing Trojan horses that are breaking through the membrane of larger cellular structure

The first and only ADC FDA approved for patients with mTNBC who have received AT LEAST 2 prior THERAPIES FOR METASTATIC DISEASE

A way in


TRODELVY attacks metastatic triple-negative breast cancer (mTNBC) with an antibody-drug conjugate (ADC) that binds to Trop-2

Based on pre-clinical data. May not correlate with clinical outcomes.

TRODELVYᵀᴹ Access Services logo

TRODELVY ACCESS SERVICES can help you navigate insurance requirements, the reimbursement process, and alternative assistance for your patients. Call 1-844-TRODELVY (1-844-876-3358), Monday–Friday, 9 AM–7 PM ET.

Learn More

Download and complete the Patient Enrollment Form to get your patients started today

Medical Information

For further information, please contact:
Phone: 1-888-983-IMMU (4668) or Email: